Grifols公布2026年上半年业绩，现金流改善并维持全年指引

Nasdaq cuts most of its losses, Dow surges on extended oil slide, solid earnings
Introduction & Market Context
Grifols (NASDAQ:GRFS) presented its H1 2026 results on July 28, 2026, confirming the Spanish plasma products company remains on track to deliver full-year guidance despite ongoing challenges in China albumin markets. The presentation highlighted a significant cash flow turnaround and sustained momentum in the immunoglobulin franchise, while detailing the company’s strategic shift toward ex-U.S. plasma self-sufficiency through its Egypt expansion.
Shares rose 3.29% to $8.01 following the presentation, reflecting investor confidence in the company’s execution and strategic direction. The stock trades within its 52-week range of $6.95 to $11.14, suggesting room for further recovery as operational improvements materialize.
Financial Performance Highlights
Grifols delivered solid first-half results with revenue reaching €3,574 million, representing 2.6% growth at constant currency despite foreign exchange headwinds. The company’s adjusted EBITDA climbed to €854 million with a margin of 23.9%, up 10 basis points year-over-year on a constant currency basis.
The following overview presents the company’s comprehensive H1 2026 financial performance and strategic achievements:
The most striking improvement came in free cash flow generation, with FCF pre-M&A reaching €91 million in H1 2026 compared to negative €12 million in the prior year period—a €103 million improvement. This turnaround reflects enhanced working capital management, normalizing capital expenditures, and disciplined cost control. Group profit increased 28.7% to €227 million, demonstrating improved operational efficiency.
Second-quarter performance showed particular strength, with EBITDA margin expanding to 25.2% and quarterly FCF pre-M&A of €98 million, indicating accelerating momentum as the year progressed.
The company maintained a leverage ratio of 4.2x, unchanged from the prior year, while liquidity strengthened to €2,030 million following successful refinancing of all 2027 maturities. Management emphasized that all near-term debt obligations have been addressed, with the next maturities not due until Q4 2028.
Biopharma Drives Revenue Growth
The biopharma division emerged as the primary growth engine, delivering 5.4% constant currency revenue growth in H1 2026. This performance was led by the immunoglobulin franchise, which posted 12.8% growth for the half, with subcutaneous immunoglobulin (SCIG) products showing particularly strong momentum at 17.7% growth.
The company’s revenue composition by segment is illustrated in the following waterfall chart:
Within the IG portfolio, both intravenous and subcutaneous formulations contributed to growth. GAMUNEX-C maintained its position in core U.S. and European markets, while XEMBIFY (SCIG) accelerated to 33.9% growth in Q2 2026, demonstrating strong physician and patient adoption. Management noted that SCIG growth "normalized" in the second quarter after exceptional first-quarter performance, yet still delivered robust double-digit expansion.
The albumin business faced continued headwinds, declining 14.2% in H1 2026 on a constant currency basis, primarily due to pricing concessions implemented in China during mid-2025. However, management indicated that demand and prescription trends in China are showing early signs of stabilization, with the pricing comparison set to normalize in the second half as the prior year adjustment rolls off the base.
Alpha-1 and specialty proteins declined 2.6% in H1 2026 but returned to growth in Q2 2026 with a 2.0% increase. The segment faced payer access challenges and reauthorization pressures in Q1 2026, which eased as the quarter progressed. The company maintained strong demand for its rabies immunoglobulin products throughout the period.
For the second half, Grifols projected mid-to-high single-digit IG growth in core markets with deliberate moderation in other markets, strong double-digit SCIG growth continuation, and stabilizing albumin comparisons as China pricing normalization completes.
Strategic Transformation: Egypt and Plasma Self-Sufficiency
Grifols outlined an ambitious strategic transformation centered on achieving ex-U.S. plasma self-sufficiency while optimizing its U.S. operations for domestic demand. The company’s Egypt plasma collection initiative represents the cornerstone of this strategy, targeting approximately 1 million liters in 2026 and scaling to 3 million liters by 2029.
The company’s biopharma operating model is being reorganized into two distinct platforms:
The U.S. platform, described as "vertically integrated" and "self-sufficient," operates approximately 280 donor centers and 2 manufacturing sites. Management emphasized the platform’s efficiency and established market position, supported by sustained mid-to-high single-digit demand growth. The company closed 29 U.S. donor centers during the period as part of network optimization, incurring approximately €40 million in one-off costs (including €25 million non-cash), which management said will create "a structurally more efficient operating model going forward."
The Rest of World (RoW) platform encompasses 130+ donor centers and 5 manufacturing sites, with strategic focus on reducing reliance on U.S. plasma through the Egypt and Canada partnerships. This approach aims to better align price-cost structures and enhance supply resilience.
The following chart illustrates the company’s plasma supply transformation strategy through 2029:
By 2029, Grifols projects that 100% of U.S. plasma will serve domestic demand, compared to 75% in 2025, with the remaining 25% currently allocated to ex-U.S. markets being redirected. Simultaneously, ex-U.S. supply is expected to increase 2.5x, with Egypt plasma representing approximately 50% of total ex-U.S. supply by 2029. This strategic realignment is designed to unlock "meaningful optimization opportunities" while maintaining consistently high quality and safety standards across the entire network.
Innovation Pipeline and Product Launches
Grifols showcased significant progress across its innovation pipeline, spanning both biopharma therapeutics and diagnostic platforms. The company’s diversified approach targets franchise expansion, new indications, and next-generation technology platforms.
In biopharma, the immunoglobulin franchise is advancing through three Phase 3 studies:
The SIGMA Phase 3 study is expanding IVIG into secondary antibody deficiency (SID), while the EXCELL Phase 3 study evaluates SCIG in SID associated with blood cancers. The XPERT Phase 3 study is advancing SCIG as a potential treatment for chronic inflammatory demyelinating polyneuropathy (CIDP), addressing competitive pressure from emerging FcRn therapies. Management noted that real-world experience suggests physicians and patients continue to value immunoglobulins for their broad mechanism of action.
The company successfully launched fibrinogen in the U.S. during Q2 2026 for congenital fibrinogen deficiency, as planned. Final-stage discussions with the FDA are underway regarding Phase 3 design for an acquired indication.
For Alpha-1, the pivotal SPARTA clinical trial is approaching completion, with the last patient visit scheduled for August 2026 and topline results expected in late Q4 2026. The randomized, placebo-controlled study tests 60 and 120 mg/kg doses for emphysema progression reduction, measured by lung density preservation over three years. A separate Phase 3 study for Alpha-1 SubQ 15% initiated in June 2026, following successful Phase 1/2 results, which could enable potential self-administration at home.
On the diagnostics front, Grifols achieved a critical 2026 milestone with the June launch of its BARCELONA platform at a flagship trade fair:
The EVANZYS blood typing system represents the next generation of gel card technology, positioned to sustain Grifols’ leadership in transfusion medicine. The platform features stronger performance, simpler workflow, and modular, trackable design.
Looking further ahead, the company outlined two additional platforms targeted for 2030 launch. The ISARD immunoassay platform aims to capture share of a $1 billion immunoassay donor screening market in transfusion medicine while opening opportunities in specialty immunoassay diagnostics. The MUNDAKA molecular platform focuses on maintaining long-term NAT leadership with high multiplexing, sensitivity, and speed capabilities.
Management noted that the dissolution of the QuidelOrtho joint venture, which impacted reported diagnostic revenues in H1 2026, will ultimately enable broader market access once these next-generation platforms launch.
EBITDA Growth and Margin Expansion
Adjusted EBITDA grew 2.4% at constant currency to €854 million, with margin expanding 10 basis points to 23.9%. The margin improvement occurred despite approximately €40 million in one-off restructuring costs and the drag from weaker USD exchange rates.
The following chart breaks down the drivers of EBITDA performance:
Biopharma EBITDA growth meaningfully outpaced group EBITDA growth, supported by sustained IG momentum, progressing Biotest operational turnaround, and plasma sourcing and footprint optimization initiatives. The company achieved operating leverage through disciplined expense management, partially offsetting the China albumin pricing impact and diagnostic repositioning costs.
Reported gross margin reached 37.1% in H1 2026 (37.6% in Q2), while adjusted gross margin—excluding one-off costs—stood at 38.6% (39.4% in Q2). The margin compression versus prior year primarily reflected the China albumin pricing concession, which is now fully reflected in the comparable base.
Management emphasized that Egypt plasma ramp-up benefits are beginning to appear in the numbers, with full margin impact expected in 2027, while U.S. donor center closures should contribute to efficiency gains in late 2026 and early 2027.
Balance Sheet Strength and Capital Structure
Grifols significantly strengthened its balance sheet during the first half through comprehensive refinancing and improved cash generation. The company successfully refinanced all 2027 maturities through a €3.1 billion equivalent Term Loan B and $2.1 billion Revolving Credit Facility, combined with a €500 million 7.5% bond redemption.
The detailed financial metrics are presented below:
Total net leverage remained stable at 4.2x, while net secured leverage stood at 2.7x. The company achieved significant and rapid credit re-rating progress, moving back into BB-space with strong support from credit investors and banks. Cash interest for 2026 is projected to be in line with 2025 or better, despite the refinancing activity.
Liquidity strengthened to €2,030 million, comprising €513 million in cash and cash equivalents plus €1,517 million in unused credit facilities, up from €1,414 million in H1 2025. The upsized Revolving Credit Facility provides increased flexibility, supported by organic cash generation through free cash flow.
The next debt maturities are not due until Q4 2028, providing significant runway for the company to execute its strategic initiatives and continue deleveraging through EBITDA growth and cash generation.
Forward-Looking Guidance and Strategic Priorities
Grifols reaffirmed its full-year 2026 guidance, targeting adjusted EBITDA margin of 25% or higher and free cash flow pre-M&A of €500-575 million. Management expressed confidence in achieving these targets based on first-half performance and visibility into second-half drivers.
The company’s strategic priorities for delivering FY 2026 guidance are summarized in the following framework:
Key levers supporting the second-half outlook include continued biopharma growth driven by sustained IG momentum, Egypt plasma ramp-up enabling strategic sourcing and cost-per-liter optimization, progressing Biotest turnaround, operational leverage through disciplined cost management, and continued improvement in FCF generation.
For immunoglobulins, management projects mid-to-high single-digit growth in core markets with deliberate lower growth in other markets, plus strong double-digit SCIG growth. Albumin comparisons should benefit from prior year pricing already reflected in the base, with some signs of stabilization in China and opportunities being pursued in U.S. and other ex-China markets. Alpha-1 and specialty proteins are expected to continue growth trajectory, with the segment on track to deliver growth for FY 2026.
CEO Nacho Abia emphasized the company’s strategic focus: "Our goal is not to maximize volume at any price, but to drive sustainable, profitable, and free cash flow growth." He described Egypt as "much more than a new plasma collection project. It is a strategic investment in the future of our business."
CFO Rahul Srinivasan noted that while donor center closures will weigh on reported results in the near term, they support long-term efficiency. When asked why free cash flow guidance was not raised after a strong first half, management indicated that timing and phasing matter, and that the company remains comfortable with the existing €500-575 million target.
The company continues to evaluate a potential IPO for its U.S. biopharma business, though no timeline was provided in the presentation. Management is also building dedicated U.S. and RoW biopharma organizations to enhance operational focus as part of the strategic reorganization.
Risks and Execution Challenges
Despite the positive trajectory, Grifols faces several execution risks and market challenges. The China albumin market remains uncertain, with recovery still in early stages despite signs of stabilization. Competitive pressure in immunoglobulins is intensifying as new therapies, including FcRn inhibitors for CIDP, enter the market, though management maintains confidence in the IG franchise’s value proposition.
The Egypt plasma expansion, while promising, requires smooth execution of collection ramp-up and integration with the broader supply chain. Any delays or operational issues could impact the timeline for achieving ex-U.S. self-sufficiency and associated margin benefits.
The Biotest turnaround remains in early stages, with management acknowledging progress but noting that improvement is not yet fully established. The diagnostic business repositioning following the QuidelOrtho dissolution will take time to demonstrate benefits, with major new platform launches not expected until 2030.
Near-term restructuring costs from the 29 U.S. donor center closures will continue to pressure reported margins, with benefits not fully materializing until late 2026 and early 2027. The company also faces ongoing foreign exchange headwinds, particularly from USD weakness, which impacted both revenue and EBITDA in the first half.
Analysts during the earnings call pressed management on immunoglobulin demand sustainability, Egypt timing, China albumin recovery, and free cash flow phasing, indicating continued investor focus on execution across these key strategic priorities.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.